HOME > BUSINESS > Govt plans to make India pharma R&D hub in 4 years

Govt plans to make India pharma R&D hub in 4 years

mediThe government is preparing for multi-billion dollar investment to push India into top five pharmaceutical innovation hubs by 2020, Assocham said.

The goal of the program will be for the country to establish global presence in pharmaceutical research by launching at a global level 1 out of every 5-10 drugs discovered in the country, the industry association added.

The effort will be with 50% public funding through its public private partnership (PPP), it said.

The Indian Government has been very active in boosting growth and investment in Indian pharmaceutical industry.

It allows 100 per cent FDI (Foreign Direct Investment) under automatic route (without prior permission) in the pharmaceuticals sector.

“FDI favourably impacts the Indian pharma industry by providing access to more capital/funds for investing in R&D, which in turn, leads to creation of more IPR,” found a study titled ‘IPR in pharmaceuticals: Balancing, innovation and access,’ jointly conducted by ASSOCHAM and TechSci Research.

The Government has been actively undertaking policy initiatives for growth of the pharmaceutical industry.

One such initiative is tax-breaks in the pharmaceutical sector. There is also a weighted tax deduction at a rate of 150% for the research and development expenditure incurred. Steps to streamline methods for development of a new drug molecule, or clinical research, etc., have also been considered.

Indian Government also launched two schemes including New Millennium Indian Technology Leadership Initiative in 2003, and the Drugs and Pharmaceuticals Research Programme in 1994-95, specially targeted at pharmaceutical research, adds the study.

The Department of Industrial Policy and Promotion (DIPP) data suggests that the drugs and pharmaceuticals sector in India has attracted FDI worth USD 1,523 million during April 2014-March 2015.

Additionally, industrial licenses are not essential in India for most of the pharmaceutical products. Hence, drug manufacturers are free to develop any drug upon approval by the Drug Control Authority.

“The act of protecting one’s innovation through a patent has initiated investments from many multinational pharmaceutical companies in India. These MNCs are looking at India for its strength in contract manufacturing and as an attractive base for research and development (R&D), particularly for conducting clinical trials and other services,” Assocham said.

Indian and foreign pharmaceutical companies are progressing with rising patented drug launches in India. The Indian Patent Office granted 2008 patents between 2010 and 2013.

The Department of Pharmaceuticals has drafted Pharma Vision 2020 document, with an aim to establish India as a leading county for end-to-end drug manufacturing and innovation. This initiative by the government aims at providing support to Indian pharmaceutical sector through state of- the-art infrastructure, internationally competitive scientific research personnel for pharmaceutical R&D, and funding for research in the public and private sectors.

The Central Drug Standard Control Organisation (CDSCO), which falls under the scope of the Ministry of Health and Family Welfare, is the main pharma regulatory body in India. The Drug Controller General of India (DCGI) presides over the CDSCO at both the central and state levels.

Sun Pharmaceuticals acquired Ranbaxy Laboratories in 2015, in order to achieve full compliance with regulatory framework for drug manufacturing in India, meet expectations of Indian regulatory authorities, and increase R&D for launch of innovative products, thereby generating high revenues across India.

Follow ULTRA.news
Suven Life Sciences gets patent for neuro drug Suven Life Sciences Ltd said it was granted a patent by New Zealand authorities for "a class of selective 5-HT4 compounds" that are being developed to treat neurodegenerative diseases.The compounds are being explored for use in cases of Alzheimer’s disease, Attention deficie...
USFDA returns Mylan-Biocon’s drug application for more data The U.S. Food and Drug Administration has sought more data before approving a chemotherapy compound submitted by Mylan and jointly developed by Biocon.The agency issued a 'complete response letter'. Such letters are issued when an FDA review an FDA review finds that an appli...
NATCO Pharma to sell multiple sclerosis drug in USA via Mylan NATCO Pharma Limited said it the US Food and Drug Administration approved the generic drug application filed by its marketing partner Mylan for injections used in the treatment of multiple sclerosis, a chronic inflammatory disease of the central nervous system.The drug, Glat...
Vivimed pharma unit gets Rs 270 cr investment from OrbiMed fund Pharmaceuticals and specialty chemicals maker Vivimed Labs said investment firm OrbiMed will invest $42.5 mn (Rs 270 cr) into its active pharmaceutical ingredients business.The investment will be into Vivimed Labs Mascarene Ltd, which is in turn the holding entity of the com...
Glenmark to launch Desonide topical ointment in US Glenmark Pharmaceuticals Inc said it has got the go-ahead to launch the generic version of Perrigo's anti-inflammation ointment Desonide Ointment in the US.Desonide Ointment, 0.05% had annual sales of approximately $23.4 million for the 12 month period ending July 2017, acco...
Biocon passes US-FDA inspection at Vishakapatanam plant Biocon said the plant inspection conducted by the US Food and Drug Administration at its Vishakapatanam plant passed without incident."US FDA inspected our Active Pharmaceutical Ingredients (API) manufacturing facility in Wishakhapatnam, Andhra Pradesh from September 11 to 1...
Zydus Cadila gets approval for two drugs in the US Zydus Cadila said it received the final regulatory approval to market anti-sleep drug Modafinil in the US, and tentative approval for bladder control drug Solifenacin Succinate.Unlike a final approval, tentative approvals don't allow the grantee to sell the drugs in the US m...
Panacea Biotec to supply heart drug to Apotex for US market Pharma company Panacea Biotec said it has signed an agreement to supply a generic version of Eli Lilly's Effient heart drug to Apotex, the largest Canadian-owned pharmaceutical company.The drug will be sold by Apotex in the US market."Under the terms of the agreement, Ap...
Modi’s reforms drag, power plants to face low loads, study India’s energy sector is facing low capacity utilisation in power generation as plant load factor is estimated to remain low at around 62 per cent until 2018-19, noted a recent ASSOCHAM-Crisil joint study.The study also expressed concern over the slow pace of reform implement...
Jubilant Life Sciences gets US-FDA approval for pain drug Pharma company Jubilant Life Sciences Ltd said it received final approval to sell pain drug Indomethacin in the US.The drug, which is also sold as Indocin by Iroko in the US, is a nonsteroidal anti-inflammatory drug used for the treatment of moderate to severe inflammation a...
Glenmark Pharma gets USFDA approval for generic version of Mylan’s anti-inflammation ointment Glenmark Pharmaceuticals said it has got the US FDA approval to sell the generic version of corticosteroid ointment Kenalog from Mylan Pharmaceuticals.The primary ingredient is triamcinolone, a corticosteroid that reduces the actions of chemicals in the body that cause inflam...
Lupin gets FDA nod for generic cholesterol drug Pharmaceuticals company Lupin said it received a 505 (b)(2) NDA approval for its Nikita"M (Pitavastatin) Tablets 1 mg, 2 mg and 4 mg from the United States Food and Drug Administration (FDA).A 505(b)(2) approval refers to one given by relying on studies already performed on a...
Strides Shasun to launch allergy drug in the US Pharma company Strides Shasun said it had received approval allergy drug Cetirizine Hydrochloride in the US."The US market for Cetirizine Hydrochloride Capsules (Softgel) is approximately USD 60 mln, with only one other generic player," the company said."The product is re...
Glenmark Pharma gets UK OTC approval for anti-malarial medicine Glenmark Pharmaceuticals said it received approval from UK authorities for to sell its Maloff Protect anti-malarial medication without prescription.It contains atovaquone and proguanil hydrochloride, and has been available only as a prescription medicine in the UK.The Me...
Sun Pharma selects Samsung to manufacture psoriasis drug Sun Pharma said it has inked a long-term agreement with Samsung BioLogics under which the Korean company will manufacture Tildrakizumab, a potential treatment for plaque psoriasis, for the Indian company.Plaque psoriasis is an autoimmune condition which results in patches of ...
GST to boost Indian electronics manufacturing – Assocham-NEC study The goods and services tax will give a big boost to domestic electronic manufacturering as costs will be significantly brought down, said a study by ASSOCHAM-NEC.“The local manufacturers will be able to pass on the tax benefit to consumers in the form of price reduction,” sai...
Strides Shasun gets USFDA nod for nausea drug Pharmaceutical company Strides Shasun said it received approval from the United States Food & Drug Administration to sell nausea drug Promethazine Hydrochloride in the country.The US market for Promethazine Hydrochloride tablets is approximately USD 17 Million.It will be ...
Unichem Labs says USFDA completes inspection of Goa facility Unichem Laboratories said the US FDA has completed its inspection of the company's formulations manufacturing facility in Goa.Unichem Labs' formulations plant in GoaThe facility has received an Establishment Inspection Report, the company added."This receipt indica...
Zydus Cadila gets approval for obesity drug in USA Zydus Cadila said it received the final approval from the US FDA to market obesity drug Phentermine Hydrochloride.The drug will be marketed in the form of orally disintegrating tablets in strengths of 15 mg, 30 mg, and 37.5 mg.The drug is used to treat obesity in people w...
Zydus Cadila gets nod to sell ADHD drug in USA Nesher Pharmaceuticals, a subsidiary of Zydus Pharmaceuticals received final approval from the US Food and Drug Administration to sell generic drug Dextroamphetamine Sulfate.Dextroamphetamine is a central nervous system stimulant used in the treatment of Attention Deficit Hyp...